New York, NY -- (SBWIRE) -- 04/08/2013 -- Sinovac Biotech Ltd. (NASDAQ:SVA) announced that it will release its unaudited financial results for the fourth quarter and full year ended December 31, 2012, before market on Thursday, April 18, 2013. The Company will host a conference call on Thursday, April 18, 2013, at 8:00 a.m. EDT (April 18, 2013, at 8:00 p.m. China Standard Time) to review the Company&aposs financial results and provide an update on recent corporate developments.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies vaccine.
Find out what could be SVA next big move here:
Bank of America reiterated their buy rating on shares of Cemex SAB de CV (NYSE:CX) in a research report sent to investors last month The firm currently has a $13.75 price target on the stock, up from their previous price target of $13.00.
Analysts at Barclays Capital had reiterated an equal weight rating on shares of Cemex SAB de CV in a research note to investors on, February 19th. They have a $11.00 price target on the stock.
Analysts at Citigroup initiated coverage on shares of Cemex SAB de CV in a research note to investors on February 4th. They had set a neutral rating and a $12.70 price target on the stock.
CEMEX SAB de CV (CEMEX) is a Mexico-based company principally engaged, through its subsidiaries, in the cement manufacturing.
Get the daily trend analysis reports on CX here:
MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.MonsterTradingAlerts.com
MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/
Alexander K. Neumann
Monster Trading Alerts
For more information on this press release visit: http://www.sbwire.com/press-releases/sinovac-biotech-cemex-sab-de-cv-reports-nasdaqsva-nysecx-234392.htm